Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2018 5
2019 8
2020 10
2021 13
2022 16
2023 14
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer.
Di Federico A, Ricciotti I, Favorito V, Michelina SV, Scaparone P, Metro G, De Giglio A, Pecci F, Lamberti G, Ambrogio C, Ricciuti B. Di Federico A, et al. Among authors: de giglio a. Curr Oncol Rep. 2023 Sep;25(9):1017-1029. doi: 10.1007/s11912-023-01436-y. Epub 2023 Jun 28. Curr Oncol Rep. 2023. PMID: 37378881 Review.
Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
Rossi S, Gelsomino F, Rinaldi R, Muccioli L, Comito F, Di Federico A, De Giglio A, Lamberti G, Andrini E, Mollica V, D'Angelo R, Baccari F, Zenesini C, Madia P, Raschi E, Cortelli P, Ardizzoni A, Guarino M. Rossi S, et al. Among authors: de giglio a. J Neurol. 2023 Jun;270(6):2975-2986. doi: 10.1007/s00415-023-11625-1. Epub 2023 Feb 17. J Neurol. 2023. PMID: 36800019 Free PMC article.
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer.
Ricciuti B, Mira A, Andrini E, Scaparone P, Michelina SV, Pecci F, Cantini L, De Giglio A, Lamberti G, Ambrogio C, Metro G. Ricciuti B, et al. Among authors: de giglio a. Drugs Context. 2022 Nov 16;11:2022-7-4. doi: 10.7573/dic.2022-7-4. eCollection 2022. Drugs Context. 2022. PMID: 36452878 Free PMC article. Review.
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies.
Favorito V, Ricciotti I, De Giglio A, Fabbri L, Seminerio R, Di Federico A, Gariazzo E, Costabile S, Metro G. Favorito V, et al. Among authors: de giglio a. Expert Opin Emerg Drugs. 2024 Apr 8:1-16. doi: 10.1080/14728214.2024.2331139. Online ahead of print. Expert Opin Emerg Drugs. 2024. PMID: 38572595 Review.
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.
Mosca M, Conci N, Di Federico A, Tateo V, Favorito V, Zappi A, Gelsomino F, De Giglio A. Mosca M, et al. Among authors: de giglio a. JCO Precis Oncol. 2023 May;7:e2300073. doi: 10.1200/PO.23.00073. JCO Precis Oncol. 2023. PMID: 37262392 Review.
67 results